Animal coronavirus vaccines : Lessons for SARS
Identifieur interne :
000277 ( PascalFrancis/Curation );
précédent :
000276;
suivant :
000278
Animal coronavirus vaccines : Lessons for SARS
Auteurs : L. J. Saif [
États-Unis]
Source :
-
Developments in biologicals [ 1424-6074 ] ; 2004.
RBID : Pascal:05-0154089
Descripteurs français
- Pascal (Inist)
- Virus syndrome respiratoire aigu sévère,
Homme,
Porcin,
Vaccin,
Chine,
Origine,
Transmission,
Réservoir,
Santé publique,
Muqueuse,
Immunité locale,
Syndrome respiratoire aigu sévère,
Maladie émergente,
Adjuvant immunologique,
Complication,
Echec,
Article synthèse.
- Wicri :
English descriptors
- KwdEn :
- China,
Complication,
Emerging disease,
Failure,
Human,
Immunological adjuvant,
Local immunity,
Mucosa,
Origin,
Public health,
Reservoir,
Review,
Severe acute respiratory syndrome,
Severe acute respiratory syndrome virus,
Swine,
Transmission,
Vaccine.
Abstract
Severe acute respiratory syndrome (SARS) emerged in China and spread globally as a human pandemic. It is caused by a new coronavirus (CoV) of suspect animal origin. The emergence of SARS stunned medical scientists, but veterinary virologists had previously recognized CoVs as causing fatal respiratory or enteric disease in animals with interspecies transmission and wildlife reservoirs. Because of its public health impact, major efforts are focused on development of SARS vaccines. Occurrence of CoV disease at mucosal surfaces necessitates the stimulation of local immunity, having an impact on the vaccine type, delivery and adjuvant needed to achieve mucosal immunity. Such immunity is often short-lived, requires frequent boosting and may not prevent re-infection, all factors complicating CoV vaccine design. SARS vaccine efforts should be enhanced by understanding the correlates of protection and reasons for the success or failure of animal CoV vaccines. This review will focus on studies of immunity and protection in swine to the enteric CoV, transmissible gastroenteritis (TGEV) versus the respiratory variant, porcine respiratory CoV (PRCV), comparing live, inactivated and subunit vaccines, various vaccine vectors, routes and adjuvants. In addition avian infectious bronchitis CoV (IBV) vaccines targeted for protection of the upper respiratory tract of chickens are discussed. Unfortunately, despite long-term efforts, effective vaccines to prevent enteric CoV infections remain elusive, and generally live, but not killed vaccines, have induced the most consistent protection against animal CoVs. Confirmation of the pathogenesis of SARS in humans or animals models that mimic SARS may further aid in vaccine design and evaluation.
| pA |
| A01 | 01 | 1 | | @0 1424-6074 |
|---|
| A03 | | 1 | | @0 Dev. biol. |
|---|
| A05 | | | | @2 119 |
|---|
| A08 | 01 | 1 | ENG | @1 Animal coronavirus vaccines : Lessons for SARS |
|---|
| A09 | 01 | 1 | ENG | @1 Control of Infectious Animal Diseases by Vaccination |
|---|
| A11 | 01 | 1 | | @1 SAIF (L. J.) |
|---|
| A12 | 01 | 1 | | @1 SCHUDEL (Alejandro) @9 ed. |
|---|
| A12 | 02 | 1 | | @1 LOMBARD (Michel) @9 ed. |
|---|
| A14 | 01 | | | @1 Food Animal Health Research Program, OARDC, The Ohio State University @2 Wooster, OH @3 USA @Z 1 aut. |
|---|
| A15 | 01 | | | @1 World Organisation for Animal Health-OIE @2 Paris @3 FRA @Z 1 aut. |
|---|
| A15 | 02 | | | @1 International Association for Biologicals (IABs) @2 Geneva @3 CHE @Z 2 aut. |
|---|
| A18 | 01 | 1 | | @1 World Organisation for Animal Health-OIE @2 Paris @3 FRA @9 patr. |
|---|
| A20 | | | | @1 129-140 |
|---|
| A21 | | | | @1 2004 |
|---|
| A23 | 01 | | | @0 ENG |
|---|
| A43 | 01 | | | @1 INIST @2 13557 @5 354000127067510090 |
|---|
| A44 | | | | @0 0000 @1 © 2005 INIST-CNRS. All rights reserved. |
|---|
| A45 | | | | @0 55 ref. |
|---|
| A47 | 01 | 1 | | @0 05-0154089 |
|---|
| A60 | | | | @1 P @2 C |
|---|
| A61 | | | | @0 A |
|---|
| A64 | 01 | 1 | | @0 Developments in biologicals |
|---|
| A66 | 01 | | | @0 CHE |
|---|
| C01 | 01 | | ENG | @0 Severe acute respiratory syndrome (SARS) emerged in China and spread globally as a human pandemic. It is caused by a new coronavirus (CoV) of suspect animal origin. The emergence of SARS stunned medical scientists, but veterinary virologists had previously recognized CoVs as causing fatal respiratory or enteric disease in animals with interspecies transmission and wildlife reservoirs. Because of its public health impact, major efforts are focused on development of SARS vaccines. Occurrence of CoV disease at mucosal surfaces necessitates the stimulation of local immunity, having an impact on the vaccine type, delivery and adjuvant needed to achieve mucosal immunity. Such immunity is often short-lived, requires frequent boosting and may not prevent re-infection, all factors complicating CoV vaccine design. SARS vaccine efforts should be enhanced by understanding the correlates of protection and reasons for the success or failure of animal CoV vaccines. This review will focus on studies of immunity and protection in swine to the enteric CoV, transmissible gastroenteritis (TGEV) versus the respiratory variant, porcine respiratory CoV (PRCV), comparing live, inactivated and subunit vaccines, various vaccine vectors, routes and adjuvants. In addition avian infectious bronchitis CoV (IBV) vaccines targeted for protection of the upper respiratory tract of chickens are discussed. Unfortunately, despite long-term efforts, effective vaccines to prevent enteric CoV infections remain elusive, and generally live, but not killed vaccines, have induced the most consistent protection against animal CoVs. Confirmation of the pathogenesis of SARS in humans or animals models that mimic SARS may further aid in vaccine design and evaluation. |
|---|
| C02 | 01 | X | | @0 002A01D |
|---|
| C02 | 02 | X | | @0 002A05C09 |
|---|
| C03 | 01 | X | FRE | @0 Virus syndrome respiratoire aigu sévère @2 NW @5 01 |
|---|
| C03 | 01 | X | ENG | @0 Severe acute respiratory syndrome virus @2 NW @5 01 |
|---|
| C03 | 01 | X | SPA | @0 Severe acute respiratory syndrome virus @2 NW @5 01 |
|---|
| C03 | 02 | X | FRE | @0 Homme @5 02 |
|---|
| C03 | 02 | X | ENG | @0 Human @5 02 |
|---|
| C03 | 02 | X | SPA | @0 Hombre @5 02 |
|---|
| C03 | 03 | X | FRE | @0 Porcin @5 04 |
|---|
| C03 | 03 | X | ENG | @0 Swine @5 04 |
|---|
| C03 | 03 | X | SPA | @0 Porcino @5 04 |
|---|
| C03 | 04 | X | FRE | @0 Vaccin @5 05 |
|---|
| C03 | 04 | X | ENG | @0 Vaccine @5 05 |
|---|
| C03 | 04 | X | SPA | @0 Vacuna @5 05 |
|---|
| C03 | 05 | X | FRE | @0 Chine @2 NG @5 06 |
|---|
| C03 | 05 | X | ENG | @0 China @2 NG @5 06 |
|---|
| C03 | 05 | X | SPA | @0 China @2 NG @5 06 |
|---|
| C03 | 06 | X | FRE | @0 Origine @5 07 |
|---|
| C03 | 06 | X | ENG | @0 Origin @5 07 |
|---|
| C03 | 06 | X | SPA | @0 Origen @5 07 |
|---|
| C03 | 07 | X | FRE | @0 Transmission @5 08 |
|---|
| C03 | 07 | X | ENG | @0 Transmission @5 08 |
|---|
| C03 | 07 | X | SPA | @0 Transmisión @5 08 |
|---|
| C03 | 08 | X | FRE | @0 Réservoir @5 09 |
|---|
| C03 | 08 | X | ENG | @0 Reservoir @5 09 |
|---|
| C03 | 08 | X | SPA | @0 Depósito @5 09 |
|---|
| C03 | 09 | X | FRE | @0 Santé publique @5 10 |
|---|
| C03 | 09 | X | ENG | @0 Public health @5 10 |
|---|
| C03 | 09 | X | SPA | @0 Salud pública @5 10 |
|---|
| C03 | 10 | X | FRE | @0 Muqueuse @5 11 |
|---|
| C03 | 10 | X | ENG | @0 Mucosa @5 11 |
|---|
| C03 | 10 | X | SPA | @0 Mucosa @5 11 |
|---|
| C03 | 11 | X | FRE | @0 Immunité locale @5 12 |
|---|
| C03 | 11 | X | ENG | @0 Local immunity @5 12 |
|---|
| C03 | 11 | X | SPA | @0 Inmunidad local @5 12 |
|---|
| C03 | 12 | X | FRE | @0 Syndrome respiratoire aigu sévère @2 NM @5 14 |
|---|
| C03 | 12 | X | ENG | @0 Severe acute respiratory syndrome @2 NM @5 14 |
|---|
| C03 | 12 | X | SPA | @0 Síndrome respiratorio agudo severo @2 NM @5 14 |
|---|
| C03 | 13 | X | FRE | @0 Maladie émergente @2 NM @5 15 |
|---|
| C03 | 13 | X | ENG | @0 Emerging disease @2 NM @5 15 |
|---|
| C03 | 13 | X | SPA | @0 Enfermedad emergente @2 NM @5 15 |
|---|
| C03 | 14 | X | FRE | @0 Adjuvant immunologique @5 67 |
|---|
| C03 | 14 | X | ENG | @0 Immunological adjuvant @5 67 |
|---|
| C03 | 14 | X | SPA | @0 Coadyuvante inmunológico @5 67 |
|---|
| C03 | 15 | X | FRE | @0 Complication @5 68 |
|---|
| C03 | 15 | X | ENG | @0 Complication @5 68 |
|---|
| C03 | 15 | X | SPA | @0 Complicación @5 68 |
|---|
| C03 | 16 | X | FRE | @0 Echec @5 69 |
|---|
| C03 | 16 | X | ENG | @0 Failure @5 69 |
|---|
| C03 | 16 | X | SPA | @0 Fracaso @5 69 |
|---|
| C03 | 17 | X | FRE | @0 Article synthèse @5 70 |
|---|
| C03 | 17 | X | ENG | @0 Review @5 70 |
|---|
| C03 | 17 | X | SPA | @0 Artículo síntesis @5 70 |
|---|
| C07 | 01 | X | FRE | @0 Coronavirus @2 NW |
|---|
| C07 | 01 | X | ENG | @0 Coronavirus @2 NW |
|---|
| C07 | 01 | X | SPA | @0 Coronavirus @2 NW |
|---|
| C07 | 02 | X | FRE | @0 Coronaviridae @2 NW |
|---|
| C07 | 02 | X | ENG | @0 Coronaviridae @2 NW |
|---|
| C07 | 02 | X | SPA | @0 Coronaviridae @2 NW |
|---|
| C07 | 03 | X | FRE | @0 Nidovirales @2 NW |
|---|
| C07 | 03 | X | ENG | @0 Nidovirales @2 NW |
|---|
| C07 | 03 | X | SPA | @0 Nidovirales @2 NW |
|---|
| C07 | 04 | X | FRE | @0 Virus @2 NW |
|---|
| C07 | 04 | X | ENG | @0 Virus @2 NW |
|---|
| C07 | 04 | X | SPA | @0 Virus @2 NW |
|---|
| C07 | 05 | X | FRE | @0 Artiodactyla @2 NS |
|---|
| C07 | 05 | X | ENG | @0 Artiodactyla @2 NS |
|---|
| C07 | 05 | X | SPA | @0 Artiodactyla @2 NS |
|---|
| C07 | 06 | X | FRE | @0 Ungulata @2 NS |
|---|
| C07 | 06 | X | ENG | @0 Ungulata @2 NS |
|---|
| C07 | 06 | X | SPA | @0 Ungulata @2 NS |
|---|
| C07 | 07 | X | FRE | @0 Mammalia @2 NS |
|---|
| C07 | 07 | X | ENG | @0 Mammalia @2 NS |
|---|
| C07 | 07 | X | SPA | @0 Mammalia @2 NS |
|---|
| C07 | 08 | X | FRE | @0 Vertebrata @2 NS |
|---|
| C07 | 08 | X | ENG | @0 Vertebrata @2 NS |
|---|
| C07 | 08 | X | SPA | @0 Vertebrata @2 NS |
|---|
| C07 | 09 | X | FRE | @0 Asie @2 NG |
|---|
| C07 | 09 | X | ENG | @0 Asia @2 NG |
|---|
| C07 | 09 | X | SPA | @0 Asia @2 NG |
|---|
| C07 | 10 | X | FRE | @0 Epidémiologie @5 13 |
|---|
| C07 | 10 | X | ENG | @0 Epidemiology @5 13 |
|---|
| C07 | 10 | X | SPA | @0 Epidemiología @5 13 |
|---|
| C07 | 11 | X | FRE | @0 Virose |
|---|
| C07 | 11 | X | ENG | @0 Viral disease |
|---|
| C07 | 11 | X | SPA | @0 Virosis |
|---|
| C07 | 12 | X | FRE | @0 Infection |
|---|
| C07 | 12 | X | ENG | @0 Infection |
|---|
| C07 | 12 | X | SPA | @0 Infección |
|---|
| C07 | 13 | X | FRE | @0 Vétérinaire @5 17 |
|---|
| C07 | 13 | X | ENG | @0 Veterinary @5 17 |
|---|
| C07 | 13 | X | SPA | @0 Veterinario @5 17 |
|---|
| N21 | | | | @1 101 |
|---|
| N44 | 01 | | | @1 OTO |
|---|
| N82 | | | | @1 OTO |
|---|
|
|---|
| pR |
| A30 | 01 | 1 | ENG | @1 Control of Infectious Animal Diseases by Vaccination. Conference @3 Buenos Aires ARG @4 2005-04-13 |
|---|
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000713
Links to Exploration step
Pascal:05-0154089
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Animal coronavirus vaccines : Lessons for SARS</title>
<author><name sortKey="Saif, L J" sort="Saif, L J" uniqKey="Saif L" first="L. J." last="Saif">L. J. Saif</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Food Animal Health Research Program, OARDC, The Ohio State University</s1>
<s2>Wooster, OH</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14><country>États-Unis</country>
</affiliation><publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0154089</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 05-0154089 INIST</idno>
<idno type="RBID">Pascal:05-0154089</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000713</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000277</idno>
</publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Animal coronavirus vaccines : Lessons for SARS</title>
<author><name sortKey="Saif, L J" sort="Saif, L J" uniqKey="Saif L" first="L. J." last="Saif">L. J. Saif</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Food Animal Health Research Program, OARDC, The Ohio State University</s1>
<s2>Wooster, OH</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14><country>États-Unis</country>
</affiliation><series><title level="j" type="main">Developments in biologicals</title>
<title level="j" type="abbreviated">Dev. biol.</title>
<idno type="ISSN">1424-6074</idno>
<imprint><date when="2004">2004</date>
</imprint><seriesStmt><title level="j" type="main">Developments in biologicals</title>
<title level="j" type="abbreviated">Dev. biol.</title>
<idno type="ISSN">1424-6074</idno>
</seriesStmt><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>China</term>
<term>Complication</term>
<term>Emerging disease</term>
<term>Failure</term>
<term>Human</term>
<term>Immunological adjuvant</term>
<term>Local immunity</term>
<term>Mucosa</term>
<term>Origin</term>
<term>Public health</term>
<term>Reservoir</term>
<term>Review</term>
<term>Severe acute respiratory syndrome</term>
<term>Severe acute respiratory syndrome virus</term>
<term>Swine</term>
<term>Transmission</term>
<term>Vaccine</term>
</keywords><keywords scheme="Pascal" xml:lang="fr"><term>Virus syndrome respiratoire aigu sévère</term>
<term>Homme</term>
<term>Porcin</term>
<term>Vaccin</term>
<term>Chine</term>
<term>Origine</term>
<term>Transmission</term>
<term>Réservoir</term>
<term>Santé publique</term>
<term>Muqueuse</term>
<term>Immunité locale</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Maladie émergente</term>
<term>Adjuvant immunologique</term>
<term>Complication</term>
<term>Echec</term>
<term>Article synthèse</term>
</keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
<term>Porcin</term>
<term>Vaccin</term>
<term>Santé publique</term>
</keywords><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) emerged in China and spread globally as a human pandemic. It is caused by a new coronavirus (CoV) of suspect animal origin. The emergence of SARS stunned medical scientists, but veterinary virologists had previously recognized CoVs as causing fatal respiratory or enteric disease in animals with interspecies transmission and wildlife reservoirs. Because of its public health impact, major efforts are focused on development of SARS vaccines. Occurrence of CoV disease at mucosal surfaces necessitates the stimulation of local immunity, having an impact on the vaccine type, delivery and adjuvant needed to achieve mucosal immunity. Such immunity is often short-lived, requires frequent boosting and may not prevent re-infection, all factors complicating CoV vaccine design. SARS vaccine efforts should be enhanced by understanding the correlates of protection and reasons for the success or failure of animal CoV vaccines. This review will focus on studies of immunity and protection in swine to the enteric CoV, transmissible gastroenteritis (TGEV) versus the respiratory variant, porcine respiratory CoV (PRCV), comparing live, inactivated and subunit vaccines, various vaccine vectors, routes and adjuvants. In addition avian infectious bronchitis CoV (IBV) vaccines targeted for protection of the upper respiratory tract of chickens are discussed. Unfortunately, despite long-term efforts, effective vaccines to prevent enteric CoV infections remain elusive, and generally live, but not killed vaccines, have induced the most consistent protection against animal CoVs. Confirmation of the pathogenesis of SARS in humans or animals models that mimic SARS may further aid in vaccine design and evaluation.</div>
</front><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1424-6074</s0>
</fA01><fA03 i2="1"><s0>Dev. biol.</s0>
</fA03><fA05><s2>119</s2>
</fA05><fA08 i1="01" i2="1" l="ENG"><s1>Animal coronavirus vaccines : Lessons for SARS</s1>
</fA08><fA09 i1="01" i2="1" l="ENG"><s1>Control of Infectious Animal Diseases by Vaccination</s1>
</fA09><fA11 i1="01" i2="1"><s1>SAIF (L. J.)</s1>
</fA11><fA12 i1="01" i2="1"><s1>SCHUDEL (Alejandro)</s1>
<s9>ed.</s9>
</fA12><fA12 i1="02" i2="1"><s1>LOMBARD (Michel)</s1>
<s9>ed.</s9>
</fA12><fA14 i1="01"><s1>Food Animal Health Research Program, OARDC, The Ohio State University</s1>
<s2>Wooster, OH</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14><fA15 i1="01"><s1>World Organisation for Animal Health-OIE</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</fA15><fA15 i1="02"><s1>International Association for Biologicals (IABs)</s1>
<s2>Geneva</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
</fA15><fA18 i1="01" i2="1"><s1>World Organisation for Animal Health-OIE</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<s9>patr.</s9>
</fA18><fA20><s1>129-140</s1>
</fA20><fA21><s1>2004</s1>
</fA21><fA23 i1="01"><s0>ENG</s0>
</fA23><fA43 i1="01"><s1>INIST</s1>
<s2>13557</s2>
<s5>354000127067510090</s5>
</fA43><fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44><fA45><s0>55 ref.</s0>
</fA45><fA47 i1="01" i2="1"><s0>05-0154089</s0>
</fA47><fA60><s1>P</s1>
<s2>C</s2>
</fA60><fA64 i1="01" i2="1"><s0>Developments in biologicals</s0>
</fA64><fA66 i1="01"><s0>CHE</s0>
</fA66><fC01 i1="01" l="ENG"><s0>Severe acute respiratory syndrome (SARS) emerged in China and spread globally as a human pandemic. It is caused by a new coronavirus (CoV) of suspect animal origin. The emergence of SARS stunned medical scientists, but veterinary virologists had previously recognized CoVs as causing fatal respiratory or enteric disease in animals with interspecies transmission and wildlife reservoirs. Because of its public health impact, major efforts are focused on development of SARS vaccines. Occurrence of CoV disease at mucosal surfaces necessitates the stimulation of local immunity, having an impact on the vaccine type, delivery and adjuvant needed to achieve mucosal immunity. Such immunity is often short-lived, requires frequent boosting and may not prevent re-infection, all factors complicating CoV vaccine design. SARS vaccine efforts should be enhanced by understanding the correlates of protection and reasons for the success or failure of animal CoV vaccines. This review will focus on studies of immunity and protection in swine to the enteric CoV, transmissible gastroenteritis (TGEV) versus the respiratory variant, porcine respiratory CoV (PRCV), comparing live, inactivated and subunit vaccines, various vaccine vectors, routes and adjuvants. In addition avian infectious bronchitis CoV (IBV) vaccines targeted for protection of the upper respiratory tract of chickens are discussed. Unfortunately, despite long-term efforts, effective vaccines to prevent enteric CoV infections remain elusive, and generally live, but not killed vaccines, have induced the most consistent protection against animal CoVs. Confirmation of the pathogenesis of SARS in humans or animals models that mimic SARS may further aid in vaccine design and evaluation.</s0>
</fC01><fC02 i1="01" i2="X"><s0>002A01D</s0>
</fC02><fC02 i1="02" i2="X"><s0>002A05C09</s0>
</fC02><fC03 i1="01" i2="X" l="FRE"><s0>Virus syndrome respiratoire aigu sévère</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03><fC03 i1="01" i2="X" l="ENG"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03><fC03 i1="01" i2="X" l="SPA"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03><fC03 i1="02" i2="X" l="FRE"><s0>Homme</s0>
<s5>02</s5>
</fC03><fC03 i1="02" i2="X" l="ENG"><s0>Human</s0>
<s5>02</s5>
</fC03><fC03 i1="02" i2="X" l="SPA"><s0>Hombre</s0>
<s5>02</s5>
</fC03><fC03 i1="03" i2="X" l="FRE"><s0>Porcin</s0>
<s5>04</s5>
</fC03><fC03 i1="03" i2="X" l="ENG"><s0>Swine</s0>
<s5>04</s5>
</fC03><fC03 i1="03" i2="X" l="SPA"><s0>Porcino</s0>
<s5>04</s5>
</fC03><fC03 i1="04" i2="X" l="FRE"><s0>Vaccin</s0>
<s5>05</s5>
</fC03><fC03 i1="04" i2="X" l="ENG"><s0>Vaccine</s0>
<s5>05</s5>
</fC03><fC03 i1="04" i2="X" l="SPA"><s0>Vacuna</s0>
<s5>05</s5>
</fC03><fC03 i1="05" i2="X" l="FRE"><s0>Chine</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03><fC03 i1="05" i2="X" l="ENG"><s0>China</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03><fC03 i1="05" i2="X" l="SPA"><s0>China</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03><fC03 i1="06" i2="X" l="FRE"><s0>Origine</s0>
<s5>07</s5>
</fC03><fC03 i1="06" i2="X" l="ENG"><s0>Origin</s0>
<s5>07</s5>
</fC03><fC03 i1="06" i2="X" l="SPA"><s0>Origen</s0>
<s5>07</s5>
</fC03><fC03 i1="07" i2="X" l="FRE"><s0>Transmission</s0>
<s5>08</s5>
</fC03><fC03 i1="07" i2="X" l="ENG"><s0>Transmission</s0>
<s5>08</s5>
</fC03><fC03 i1="07" i2="X" l="SPA"><s0>Transmisión</s0>
<s5>08</s5>
</fC03><fC03 i1="08" i2="X" l="FRE"><s0>Réservoir</s0>
<s5>09</s5>
</fC03><fC03 i1="08" i2="X" l="ENG"><s0>Reservoir</s0>
<s5>09</s5>
</fC03><fC03 i1="08" i2="X" l="SPA"><s0>Depósito</s0>
<s5>09</s5>
</fC03><fC03 i1="09" i2="X" l="FRE"><s0>Santé publique</s0>
<s5>10</s5>
</fC03><fC03 i1="09" i2="X" l="ENG"><s0>Public health</s0>
<s5>10</s5>
</fC03><fC03 i1="09" i2="X" l="SPA"><s0>Salud pública</s0>
<s5>10</s5>
</fC03><fC03 i1="10" i2="X" l="FRE"><s0>Muqueuse</s0>
<s5>11</s5>
</fC03><fC03 i1="10" i2="X" l="ENG"><s0>Mucosa</s0>
<s5>11</s5>
</fC03><fC03 i1="10" i2="X" l="SPA"><s0>Mucosa</s0>
<s5>11</s5>
</fC03><fC03 i1="11" i2="X" l="FRE"><s0>Immunité locale</s0>
<s5>12</s5>
</fC03><fC03 i1="11" i2="X" l="ENG"><s0>Local immunity</s0>
<s5>12</s5>
</fC03><fC03 i1="11" i2="X" l="SPA"><s0>Inmunidad local</s0>
<s5>12</s5>
</fC03><fC03 i1="12" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03><fC03 i1="12" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03><fC03 i1="12" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03><fC03 i1="13" i2="X" l="FRE"><s0>Maladie émergente</s0>
<s2>NM</s2>
<s5>15</s5>
</fC03><fC03 i1="13" i2="X" l="ENG"><s0>Emerging disease</s0>
<s2>NM</s2>
<s5>15</s5>
</fC03><fC03 i1="13" i2="X" l="SPA"><s0>Enfermedad emergente</s0>
<s2>NM</s2>
<s5>15</s5>
</fC03><fC03 i1="14" i2="X" l="FRE"><s0>Adjuvant immunologique</s0>
<s5>67</s5>
</fC03><fC03 i1="14" i2="X" l="ENG"><s0>Immunological adjuvant</s0>
<s5>67</s5>
</fC03><fC03 i1="14" i2="X" l="SPA"><s0>Coadyuvante inmunológico</s0>
<s5>67</s5>
</fC03><fC03 i1="15" i2="X" l="FRE"><s0>Complication</s0>
<s5>68</s5>
</fC03><fC03 i1="15" i2="X" l="ENG"><s0>Complication</s0>
<s5>68</s5>
</fC03><fC03 i1="15" i2="X" l="SPA"><s0>Complicación</s0>
<s5>68</s5>
</fC03><fC03 i1="16" i2="X" l="FRE"><s0>Echec</s0>
<s5>69</s5>
</fC03><fC03 i1="16" i2="X" l="ENG"><s0>Failure</s0>
<s5>69</s5>
</fC03><fC03 i1="16" i2="X" l="SPA"><s0>Fracaso</s0>
<s5>69</s5>
</fC03><fC03 i1="17" i2="X" l="FRE"><s0>Article synthèse</s0>
<s5>70</s5>
</fC03><fC03 i1="17" i2="X" l="ENG"><s0>Review</s0>
<s5>70</s5>
</fC03><fC03 i1="17" i2="X" l="SPA"><s0>Artículo síntesis</s0>
<s5>70</s5>
</fC03><fC07 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07><fC07 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07><fC07 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07><fC07 i1="02" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07><fC07 i1="02" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07><fC07 i1="02" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07><fC07 i1="03" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07><fC07 i1="03" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07><fC07 i1="03" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07><fC07 i1="04" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07><fC07 i1="04" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07><fC07 i1="04" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07><fC07 i1="05" i2="X" l="FRE"><s0>Artiodactyla</s0>
<s2>NS</s2>
</fC07><fC07 i1="05" i2="X" l="ENG"><s0>Artiodactyla</s0>
<s2>NS</s2>
</fC07><fC07 i1="05" i2="X" l="SPA"><s0>Artiodactyla</s0>
<s2>NS</s2>
</fC07><fC07 i1="06" i2="X" l="FRE"><s0>Ungulata</s0>
<s2>NS</s2>
</fC07><fC07 i1="06" i2="X" l="ENG"><s0>Ungulata</s0>
<s2>NS</s2>
</fC07><fC07 i1="06" i2="X" l="SPA"><s0>Ungulata</s0>
<s2>NS</s2>
</fC07><fC07 i1="07" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07><fC07 i1="07" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07><fC07 i1="07" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07><fC07 i1="08" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07><fC07 i1="08" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07><fC07 i1="08" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07><fC07 i1="09" i2="X" l="FRE"><s0>Asie</s0>
<s2>NG</s2>
</fC07><fC07 i1="09" i2="X" l="ENG"><s0>Asia</s0>
<s2>NG</s2>
</fC07><fC07 i1="09" i2="X" l="SPA"><s0>Asia</s0>
<s2>NG</s2>
</fC07><fC07 i1="10" i2="X" l="FRE"><s0>Epidémiologie</s0>
<s5>13</s5>
</fC07><fC07 i1="10" i2="X" l="ENG"><s0>Epidemiology</s0>
<s5>13</s5>
</fC07><fC07 i1="10" i2="X" l="SPA"><s0>Epidemiología</s0>
<s5>13</s5>
</fC07><fC07 i1="11" i2="X" l="FRE"><s0>Virose</s0>
</fC07><fC07 i1="11" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07><fC07 i1="11" i2="X" l="SPA"><s0>Virosis</s0>
</fC07><fC07 i1="12" i2="X" l="FRE"><s0>Infection</s0>
</fC07><fC07 i1="12" i2="X" l="ENG"><s0>Infection</s0>
</fC07><fC07 i1="12" i2="X" l="SPA"><s0>Infección</s0>
</fC07><fC07 i1="13" i2="X" l="FRE"><s0>Vétérinaire</s0>
<s5>17</s5>
</fC07><fC07 i1="13" i2="X" l="ENG"><s0>Veterinary</s0>
<s5>17</s5>
</fC07><fC07 i1="13" i2="X" l="SPA"><s0>Veterinario</s0>
<s5>17</s5>
</fC07><fN21><s1>101</s1>
</fN21><fN44 i1="01"><s1>OTO</s1>
</fN44><fN82><s1>OTO</s1>
</fN82><pR><fA30 i1="01" i2="1" l="ENG"><s1>Control of Infectious Animal Diseases by Vaccination. Conference</s1>
<s3>Buenos Aires ARG</s3>
<s4>2005-04-13</s4>
</fA30>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000277 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000277 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:05-0154089
|texte= Animal coronavirus vaccines : Lessons for SARS
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021 |  |
